›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Tempus xO assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
TempusType:
Laboratory Developed Test
Related tests:
The Tempus xO assay interrogates alterations in 1,711 genes using DNA sequencing in combination with whole transcriptome RNA sequencing of a patient’s FFPE tumor tissue and matched normal saliva or blood. The assay is designed to identify actionable oncologic variants in a wide array of solid tumor types and is capable of detecting both germline and somatic single nucleotide polymorphisms (SNPs), indels less than 100 bp, copy number variants, chromosomal rearrangements containing one or more RNA coding sequences and gene expression.
Cancer:
Solid Tumor
Gene:
ABCC1 (ATP Binding Cassette Subfamily C Member 1), ABCC2 (ATP Binding Cassette Subfamily C Member 2), AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ARID1A (AT-rich interaction domain 1A)
See More ...
ABCC1 (ATP Binding Cassette Subfamily C Member 1), ABCC2 (ATP Binding Cassette Subfamily C Member 2), AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ARID1A (AT-rich interaction domain 1A), ARID1B (AT-Rich Interaction Domain 1B), ARID2 (AT-Rich Interaction Domain 2), ASXL1 (ASXL Transcriptional Regulator 1), BARD1 (BRCA1 Associated RING Domain 1), CDK4 (Cyclin-dependent kinase 4), CDKN1A (Cyclin-dependent kinase inhibitor 1A), CDKN1B (Cyclin dependent kinase inhibitor 1B), CDKN1C (Cyclin Dependent Kinase Inhibitor 1C), DDR2 (Discoidin domain receptor 2), DNMT1 (DNA methyltransferase 1), DNMT3A (DNA methyltransferase 1), DNMT3B (DNA Methyltransferase 3 Beta), EPCAM (Epithelial cell adhesion molecule), ER (Estrogen receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), FANCA (FA Complementation Group A), FANCC (FA Complementation Group C), FGF10 (Fibroblast Growth Factor 10), FGFR1 (Fibroblast growth factor receptor 1), FLT1 (Fms-related tyrosine kinase 1), FLT3 (Fms-related tyrosine kinase 3), GATA1 (GATA Binding Protein 1), GATA2 (GATA Binding Protein 2), GATA3 (GATA binding protein 3), HDAC1 (Histone Deacetylase 1), HDAC11 (Histone Deacetylase 11), HDAC2 (Histone deacetylase 2), HER-2 (Human epidermal growth factor receptor 2), POLE (DNA Polymerase Epsilon), SMAD2 (SMAD Family Member 2), SMAD3 (SMAD Family Member 3), TGFB1 (Transforming Growth Factor Beta 1), TGFB2 (Transforming Growth Factor Beta 2), TOP2A (DNA topoisomerase 2-alpha), TRIM24 (Tripartite Motif Containing 24), TRIM33 (Tripartite Motif Containing 33), VEGFA (Vascular endothelial growth factor A), VEGFB (Vascular Endothelial Growth Factor B)
Method:
Next-Generation Sequencing (NGS)
